We also hypothesized that the potential clinical applicability of this screen goes beyond breast and ovarian cancer, since it may identify genes which can be targeted for cancer therapy in combination with PARP10 inhibitors, regardless of the PARP10 overexpression status. The gene discussed is PARP10; the disease is ovarian cancer.